What happened: ANVISA approval for Sun’s semaglutide injection in Brazil
Sun Pharmaceutical Industries announced that Brazil’s drug regulator ANVISA approved Sun to manufacture and market semaglutide injection in Brazil. Sun stated that it plans to launch the semaglutide product soon in partnership with Hypera Pharma.
Product plan for the Brazilian market
Sun indicated the following product format and strengths for semaglutide in Brazil:
Pre-filled multi-dose injectable penTwo strengths: 2 mg/1.5 mL and 4 mg/3 mLDosing schedule supported by the pen strengths: once-weekly dosing
Market context cited by Sun
Related current affairs
- Update on incentives disbursed under PLI Schemes for Pharmaceuticals, Bulk Drugs and Medical Devices
- District-wise number of Jan Aushadhi Kendras in Assam (as on 30.06.2026)
- Schemes to strengthen pharmaceutical and bulk drug manufacturing in Maharashtra
- Schemes to promote indigenous manufacturing of high-end and high-precision medical devices (PLI, Medical Device Parks, SMDI)
- Steps to reduce import dependence: PLI schemes for pharma/medical devices, urea self-sufficiency measures, and NBS policy actions for P&K fertilizers
- Trump warns of 200% tax on drug imports